JP2022551199A5 - - Google Patents

Info

Publication number
JP2022551199A5
JP2022551199A5 JP2022546592A JP2022546592A JP2022551199A5 JP 2022551199 A5 JP2022551199 A5 JP 2022551199A5 JP 2022546592 A JP2022546592 A JP 2022546592A JP 2022546592 A JP2022546592 A JP 2022546592A JP 2022551199 A5 JP2022551199 A5 JP 2022551199A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
compound according
cr6r7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022546592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551199A (ja
JP7780440B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054393 external-priority patent/WO2021071832A1/en
Publication of JP2022551199A publication Critical patent/JP2022551199A/ja
Publication of JP2022551199A5 publication Critical patent/JP2022551199A5/ja
Application granted granted Critical
Publication of JP7780440B2 publication Critical patent/JP7780440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022546592A 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 Active JP7780440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911648P 2019-10-07 2019-10-07
US62/911,648 2019-10-07
PCT/US2020/054393 WO2021071832A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers

Publications (3)

Publication Number Publication Date
JP2022551199A JP2022551199A (ja) 2022-12-07
JP2022551199A5 true JP2022551199A5 (https=) 2024-05-20
JP7780440B2 JP7780440B2 (ja) 2025-12-04

Family

ID=75438321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546592A Active JP7780440B2 (ja) 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物

Country Status (10)

Country Link
US (1) US20230049231A1 (https=)
EP (1) EP4041405A4 (https=)
JP (1) JP7780440B2 (https=)
KR (1) KR20220079878A (https=)
AU (1) AU2020362118A1 (https=)
BR (1) BR112022006292A2 (https=)
CA (1) CA3157020A1 (https=)
IL (1) IL291866A (https=)
MX (1) MX2022004178A (https=)
WO (1) WO2021071832A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003841A (es) 2020-10-06 2023-06-23 De Shaw Res Llc Compuestos lactámicos como bloqueadores del canal agitador de potasio kv1.3.
TW202521512A (zh) 2023-07-31 2025-06-01 美商美國禮來大藥廠 Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
WO2025161144A1 (zh) * 2024-01-29 2025-08-07 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
JP4377231B2 (ja) * 2001-11-05 2009-12-02 大日本住友製薬株式会社 新規なカルバペネム化合物
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
WO2005030729A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
WO2011073273A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators

Similar Documents

Publication Publication Date Title
JP2022550640A5 (https=)
JP2022551199A5 (https=)
JP2022551197A5 (https=)
JP2022552445A5 (https=)
JP2022550641A5 (https=)
CN104619698B (zh) 吡咯烷衍生物及其作为补体途径调节剂的用途
JP2019163290A5 (https=)
NZ571691A (en) Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
JP7851934B2 (ja) 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物
WO2021071821A1 (en) Arylmethylene aromatic compounds as kv1.3 potassium shaker channel blockers
EA034015B1 (ru) Модуляторы р2х7
CN118632834A (zh) 用于治疗神经变性疾病的含有羧酸的茚满基化合物
CN117500785A (zh) 用于治疗神经退化性疾病的含羧酸氮杂环丁烷基化合物
WO2021115375A1 (zh) 含氮杂环类自分泌运动因子抑制剂及其组合物和用途
CN115667236A (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
WO2022217118A1 (en) Pyrimidine based ras modulators and uses thereof
US11136330B2 (en) Synthesis of labeled imidazo[1,2-A]pyrimidines
JP2022551198A5 (https=)
CN111434653A (zh) 三氮唑类化合物及其制备方法与用途
JP2022526015A5 (https=)
JP2024525150A5 (https=)
CN115667272A (zh) 一类jak激酶抑制剂及其制备和应用
WO2018141955A1 (de) Verfahren zur herstellung halogenierter imidazopyridinderivate
WO2024019957A1 (en) Compounds for the treatment of neurodegenerative diseases
JP2025124692A (ja) 神経障害の治療に使用するための化合物